Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$7.65 - $15.51 $239,445 - $485,463
31,300 New
31,300 $462,000
Q2 2022

Aug 12, 2022

BUY
$8.59 - $20.77 $111,670 - $270,010
13,000 Added 27.31%
60,600 $766,000
Q1 2022

May 13, 2022

BUY
$15.52 - $35.65 $606,832 - $1.39 Million
39,100 Added 460.0%
47,600 $901,000
Q4 2021

Feb 09, 2022

SELL
$28.89 - $35.33 $820,476 - $1 Million
-28,400 Reduced 76.96%
8,500 $298,000
Q3 2021

Nov 12, 2021

BUY
$35.66 - $42.94 $400,818 - $482,645
11,240 Added 43.8%
36,900 $1.35 Million
Q2 2021

Aug 12, 2021

SELL
$23.7 - $39.27 $336,540 - $557,634
-14,200 Reduced 35.62%
25,660 $1.01 Million
Q1 2021

May 13, 2021

SELL
$27.01 - $36.8 $18,907 - $25,759
-700 Reduced 1.73%
39,860 $1.13 Million
Q4 2020

Feb 10, 2021

SELL
$27.51 - $34.36 $209,076 - $261,136
-7,600 Reduced 15.78%
40,560 $1.3 Million
Q3 2020

Nov 12, 2020

SELL
$25.8 - $34.61 $278,640 - $373,788
-10,800 Reduced 18.32%
48,160 $1.56 Million
Q2 2020

Aug 12, 2020

BUY
$17.65 - $28.05 $8,825 - $14,025
500 Added 0.86%
58,960 $1.63 Million
Q1 2020

May 14, 2020

BUY
$15.19 - $29.51 $343,294 - $666,926
22,600 Added 63.02%
58,460 $1.04 Million
Q4 2019

Feb 11, 2020

BUY
$17.17 - $25.95 $22,321 - $33,735
1,300 Added 3.76%
35,860 $899,000
Q3 2019

Nov 12, 2019

BUY
$17.84 - $22.69 $164,128 - $208,748
9,200 Added 36.28%
34,560 $617,000
Q2 2019

Aug 12, 2019

BUY
$22.0 - $31.78 $103,400 - $149,366
4,700 Added 22.75%
25,360 $558,000
Q1 2019

May 15, 2019

BUY
$21.27 - $30.58 $165,055 - $237,300
7,760 Added 60.16%
20,660 $632,000
Q4 2018

Feb 13, 2019

BUY
$23.09 - $37.69 $297,861 - $486,200
12,900 New
12,900 $298,000

Others Institutions Holding HCM

About HUTCHMED (China) Ltd


  • Ticker HCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 172,955,008
  • Market Cap $3.11B
  • Description
  • HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...
More about HCM
Track This Portfolio

Track Korea Investment Corp Portfolio

Follow Korea Investment Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Korea Investment Corp, based on Form 13F filings with the SEC.

News

Stay updated on Korea Investment Corp with notifications on news.